Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.What are the subtypes of NSCLC?Squamous cell carcinoma is found in cells that line the airways of the lungs. It is usually found in the middle of the lung. Adenocarcinoma is found in cells that produce mucus. It...
Oncologists have a variety of medications and therapies to treat non-small cell lung cancer (NSCLC) during its various stages. Chemotherapy, radiation, targeted therapy and corticosteroids and pain medication to help with the symptoms like inflammation. Medications for non-small celllung cancer(NSCLC)...
DB11963DacomitinibA medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution. DB00773EtoposideA podophyllotoxin derivative used to treat testicular and small cell lung tumors. DB00762IrinotecanA topoisomerase inhibitor used to treat metastatic carcinom...
non-small cell lung cancerObjective:Based on data mining technology, we attempted to explore the medication rules of modern traditional Chinese medicine (TCM)compounds in non-small cell lung cancer (NSCLC) treatment, to provide a reference for clinical drug use. Methods:From 2010 to 2017, TCM ...
(1.1) Non-Small Cell Lung Cancer (NSCLC) • in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. (1.2) • in combination with carboplatin and either paclitaxel or ...
Non-small cell lung cancer (NSCLC) remains an ongoing health concern, with poor treatment options and prognosis for many patients. Typically, individuals with lung cancer are detected at the middle and terminal stages, resulting in poor medical results d
After you're diagnosed with non-small-celllung cancer(NSCLC) that has spread (metastatic), you'll likely get treatments like chemotherapy, radiation, targeted therapy, and immunotherapy. They may help you live longer and lessen symptoms so you feel better. ...
Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of molecular response-adaptive immuno-chemotherapy for patients with lung cancer. In the
The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer. The FDA today approved a new indication for ramucirumab (Cyramza) for the treatment of metastatic non-small cell lung cancer (NSCLC). The drug was approved on April 21, 2014, ...
The formation and progression of non-small cell lung cancer(NSCLC) is the result that impaired local cells adapt and transcend the severe microenvironment by malignant proliferation,so they have not only the physiological nature and homogeneity but also pathological essence and heterogeneity.So the reas...